Who makes PF-06700841 15 mg?

PF-06700841 15 mg is developed by Pfizer Inc..

What development phase is PF-06700841 15 mg in?

PF-06700841 15 mg is in Phase 2.

What are the side effects of PF-06700841 15 mg?

Common side effects include COVID-19, Urinary tract infection, Nasopharyngitis, Upper respiratory tract infection, Diarrhoea, Nausea.

What is the generic name of PF-06700841 15 mg?

pf-06700841-15-mg is the generic (nonproprietary) name of PF-06700841 15 mg.

Last reviewed 2026-04-20 · How we verify

PF-06700841 15 mg (pf-06700841-15-mg)

Pfizer Inc. · Phase 2 active Quality 5/100

At a glance

Generic name	pf-06700841-15-mg
Sponsor	Pfizer Inc.
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

COVID-19
Urinary tract infection
Nasopharyngitis
Upper respiratory tract infection
Diarrhoea
Nausea
Headache
Cystitis
Vomiting
Blood creatine phosphokinase increased
Fatigue
Oral candidiasis

Key clinical trials

A DOSE-RANGING STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-06700841 IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

PF-06700841 15 mg CI brief — competitive landscape report
PF-06700841 15 mg updates RSS · CI watch RSS
Pfizer Inc. portfolio CI